- Home
- CINT vs VSTM Comparison
CINT vs VSTM Comparison
Compare CINT & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CINT | VSTM |
|---|---|---|
| Founded | 1995 | 2010 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 566.6M | 470.7M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | CINT | VSTM |
|---|---|---|
| Price | $4.95 | $5.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $7.00 | ★ $14.50 |
| AVG Volume (30 Days) | 193.6K | ★ 1.6M |
| Earning Date | 03-11-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.10 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $467,906,000.00 | $13,379,000.00 |
| Revenue This Year | $13.00 | $208.54 |
| Revenue Next Year | $12.62 | $251.40 |
| P/E Ratio | $18.16 | ★ N/A |
| Revenue Growth | 1.90 | ★ 33.79 |
| 52 Week Low | $3.98 | $4.01 |
| 52 Week High | $7.50 | $11.25 |
Technical Indicators
Market Signals| Indicator | CINT | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 52.95 | 39.85 |
| Support Level | $4.84 | $5.80 |
| Resistance Level | $5.16 | $6.81 |
| Average True Range (ATR) | 0.23 | 0.40 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 24.53 | 13.60 |
Price Performance
Historical ComparisonAbout CINT CI&T Inc
CI&T Inc is engaged in providing plans, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.